NCT01820767View on ClinicalTrials.gov

Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

March 31, 2014

Conditions
Chronic Kidney Disease
Interventions
DRUG

Paricalcitol

Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.

DRUG

Paricalcitol, atorvastatin

"Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.~Atorvastatin: 20 mg/day oral (1 take) during 12 weeks."

DRUG

Atorvastatin

Atorvastatin: 20 mg/day oral (1 take) during 12 weeks

Trial Locations (2)

24008

Hospital de León, León

24411,

Hospital El Bierzo. Servicio de Nefrología., Ponferrada

All Listed Sponsors
lead

Ricardo Mouzo Mirco

OTHER

NCT01820767 - Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients | Biotech Hunter | Biotech Hunter